참고문헌
- Beckman G, Birgander Z, Sjalander A, et al (1994). Is p53 polymorphism maintained by natural selection? Hum Hered, 44, 266-70. https://doi.org/10.1159/000154228
- BenYehuda D, Krichevsky S, Caspi O, et al (1996). Microsatellite instability and p53 mutation in therapy-related leukemia suggest mutator photypes, Blood, 88, 3022-6.
- Bergamaschi D, Samuels Y, Sullivan A, et al (2006). iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet, 38, 1133-41. https://doi.org/10.1038/ng1879
- Crook T, Ludwing RL, Marston N, et al (1996). Sensitivity of p53 lysine mutants to ubiqitin-directed degradation targeted by human papillomavirus. Virology, 217, 285-92. https://doi.org/10.1006/viro.1996.0115
- Donehower LA, Bardley A (1993). The tumor suppressor p53. Biochimica et Biophysica Act, 1155, 181-205.
- Dumont Patrick, J. I-Ju Leu , Anthony C, et al (2003). The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nature Genetics, 33, 357-65. https://doi.org/10.1038/ng1093
- Fenaux P, Preudhomme C, Quiquandon I, et al (1992). Mutation of the p53 gene in acute myeloid leukemia. Br J Haematol, 80, 178-83. https://doi.org/10.1111/j.1365-2141.1992.tb08897.x
- Fenaux P, Preudhomme C, Quiquandon I, et al (1991). TP53 gene mutation in acute myeloid leukemia with 17p monosomy. Blood, 78, 1652-7.
- Gottlieb E, Moshe O (1998). P53 facilitates pRb cleavage in IL-3-deprived cells: novel pro-apoptotic activity of p53. EMBO J, 17, 3587-96. https://doi.org/10.1093/emboj/17.13.3587
- Greenblatt MS, Bennett Wp, Hollstein M, et al (1994). Mutation in the p53 tumor suppressor gene.clues to cancer etiology and molecular pathogenesis. Cancer Res, 54, 4855-78.
- Hollstein M, Shomer B, Greenblatt M, et al (1996) . Datebase of p53 gene somatic mutation in human tumors and cell lines. Nul. Acids Res, 24, 141-6. https://doi.org/10.1093/nar/24.1.141
- Hu G, Zhang W, Deisseroth AB (1992). P53 gene mutations myelogenous leukaemia. Br J Haematol, 81, 489-94. https://doi.org/10.1111/j.1365-2141.1992.tb02979.x
- Ko LJ, Prives C (1996). p53: puzzle and paradigm. Genes Dev, 10, 1054-72. https://doi.org/10.1101/gad.10.9.1054
- Lahari D, Nuremberg J (1991). A rapid non-enzymatic method for the preparation of HMW DNA from blood RFLP studies. Nucleic Acid Research, 19, 5444-?. https://doi.org/10.1093/nar/19.19.5444
- Lane DP, Benchimol S (1990). p53: oncogene or anti-oncogene? Genes & Development, 4, 1-8. https://doi.org/10.1101/gad.4.1.1
- Martin MC, Jost CA, Brooks LA, et al (2000). A common polymorphism acts as an intragenic modifier of mutant p53 behavior. Nat Genet, 25, 47-54. https://doi.org/10.1038/75586
- Nigro JM, Baker SJ, Preisinger AC Jessup JM, et al (1989). Mutation in the p53 gene occur in diverse human tumour types. Nature, 342, 705-8. https://doi.org/10.1038/342705a0
- Nurbuyru, Hatice Tigli, Nejat Dalay (2003). p53 codon 72 polymorphism in breast cancer. Oncology Reports, 10, 711-4.
- Olivier M, Eeles R, Hollstein M, et al. (2002) Hum Mutat, 19, 607-14. https://doi.org/10.1002/humu.10081
- Preudhomme C, Fenaux P (1997). the clinical significance of mutation of the p53 tumor suppressor gene in haematological malignances. Br J Haematol, 98, 502.
- Prives C (1998). Signaling to p53: Breaking the MDM2-p53 circuit. Cell, 95, 5-8. https://doi.org/10.1016/S0092-8674(00)81774-2
- Siddique MM, Balram C, Fiszer-Maliszewska L, et al (2005). Evidence for selective expression of the p53 codon 72 polymorphs: implications in cancer development. Cancer Epidemiol Biomarkers Prev, 14, 2245-52. https://doi.org/10.1158/1055-9965.EPI-05-0153
- Slingerland JM, Minden MD. Benchimol S (1991). Mutation of the p53 gene in human acute myelogenous Leukemia. Blood, 77, 1500-7.
- Sugimoto K, Toyoshima H, et al (1992). Frequent mutation in the p53 gene in human myloid leukemia cell lines. Blood, 79, 2378-883.
- Teodoro J.G, Sara K, Evans, et al (2007). Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome: J Mol Med, 85, 1175-86. https://doi.org/10.1007/s00109-007-0221-2
- Thomas M, Kalita A, Labrecque S, et al (1999). Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol, 19, 1092-100. https://doi.org/10.1128/MCB.19.2.1092
- Wang YC, Lee HS, Chen Sk, et al (1999). Prognostic significance of p53 in growth control and neoplasia. Eur J Cancer, 35, 226-30. https://doi.org/10.1016/S0959-8049(98)00369-4
- Weston A, Ling-Cawley HM, Caporaso NE, et al (1994). Determination of the allelic frequencies of an L-myc and a p53polymorphism in human lung cancer. Carcinogenesis, 15, 583-7. https://doi.org/10.1093/carcin/15.4.583
피인용 문헌
- Prognostic Significance of TP53 Mutations and Single Nucleotide Polymorphisms in Acute Myeloid Leukemia: A case Series and Literature Review vol.15, pp.4, 2014, https://doi.org/10.7314/APJCP.2014.15.4.1603
- RNA-Seq analysis identifies aberrant RNA splicing of TRIP12 in acute myeloid leukemia patients at remission vol.35, pp.10, 2014, https://doi.org/10.1007/s13277-014-2228-y
- No evidence of correlation between p53 codon 72 G > C gene polymorphism and cancer risk in Indian population: a meta-analysis vol.35, pp.9, 2014, https://doi.org/10.1007/s13277-014-2114-7
- Prognostic Value of a CYP2B6 Gene Polymorphism in Patients with Acute Myeloid Leukemia vol.16, pp.11, 2015, https://doi.org/10.7314/APJCP.2015.16.11.4583
- No Evidence of Association of the Arg72Pro p53 Gene Polymorphism with Cancer Risk in the Saudi Population: a Meta-Analysis vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5663
- mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation vol.172, pp.6, 2016, https://doi.org/10.1111/bjh.13912
- Association between TP53 Arg72Pro polymorphism and leukemia risk: a meta-analysis of 14 case-control studies vol.6, pp.1, 2016, https://doi.org/10.1038/srep24097
- acute myeloid leukaemia - results of two cohort studies involving 215 patients and 3759 controls pp.00071048, 2018, https://doi.org/10.1111/bjh.14527